The life sciences landscape has changed significantly in recent decades, and will continue to do so at pace.1 The rise of ...

She is medical director of the neurology clinic at Parkland Hospital (Dallas TX, USA), where she founded and runs the myasthenia gravis programme. What has been the greatest achievement of your career ...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

J&J seeks EU approval of nipocalimab to treat people living with generalised myasthenia gravis: Beerse, Belgium Saturday, September 14, 2024, 13:30 Hrs [IST] Janssen-Cilag Interna ...

The potential value of these biomarkers may help differentiate acetylcholine receptor antibody seropositive (AChR+) myasthenia gravis (MG) from healthy patients. The potential value of these ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of the Marketing Authorisation Application to ...

MG results in weakness of the skeletal muscles and affects the voluntary muscles of the body. Muscles around people’s eyes, ...

If integrated into clinical practice, the approach could fill a need for more optimal diagnostic approaches for myasthenia ...

Myasthenia gravis (MG) and idiopathic inflammatory myopathy (IIM) are autoimmune diseases of the nervous system, and their main clinical manifestation is muscle weakness. The concurrent presence of ...

Myasthenia gravis (MG) is an autoimmune condition that manifests through muscle weakness. From drooping eyelids to difficulty ...

J&J’s BLA was supported by data from the Phase III VIVACITY study, demonstrating the safety and efficacy of biweekly ...